Jaktinib Versus Hydroxycarbamide in Subjects With Intermediate-2 or High-risk Myelofibrosis

NCT04617028 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

105

Enrollment

INDUSTRY

Sponsor class

Conditions

Myelofibrosis

Interventions

DRUG: Jaktinib
DRUG: Placebo to match Hydroxycarbamide
DRUG: Hydroxycarbamide Tablets
DRUG: Placebo to match Jaktinib

Sponsor

Suzhou Zelgen Biopharmaceuticals Co.,Ltd